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ABSTRACT: Variants of unknown significance in the CAPN3 gene constitute a significant challenge 
for genetic counselling. Despite the frequency of intronic nucleotide changes in this gene (15-25% 
of all mutations), so far their pathogenicity has only been inferred by in-silico analysis, and 
occasionally, proven by RNA analysis. In this study, 5 different intronic variants (one novel) that 
bioinformatic tools predicted would affect RNA splicing, underwent comprehensive studies which 
were designed to prove they are disease-causing. Muscle mRNA from 15 calpainopathy patients 
was analyzed by RT-PCR and splicing-specific-PCR tests. We established the previously 
unrecognized pathogenicity of these mutations, which caused aberrant splicing, most frequently by 
the activation of cryptic splicing sites or, occasionally, by exon skipping. The absence or severe 
reduction of protein demonstrated their deleterious effect at translational level. We concluded that 
bioinformatic tools are valuable to suggest the potential effects of intronic variants; however, the 
experimental demonstration of the pathogenicity is not always easy to do even when using RNA 
analysis (low abundance, degradation mechanisms), and it might not be successful unless splicing-
specific-PCR tests are used. A comprehensive approach is therefore recommended to identify and 
describe unclassified variants in order to offer essential data for basic and clinical geneticists. 
©2010 Wiley-Liss, Inc. 
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INTRODUCTION 
Autosomal recessive limb girdle muscular dystrophies (LGMD) are a group of disorders characterized by 
progressive involvement of proximal limb girdle muscles, including at least 14 different genetic entities. 
LGMD2A [MIM# 253600] is the most prevalent form of LGMD in many countries, and is caused by mutations in 
the CAPN3 gene [MIM# 114240] encoding calpain-3 protein. About 350 different CAPN3 gene mutations have so 
far been reported on the Leiden Muscular Dystrophy Database, most of which are private and distributed 
throughout the gene. Approximately 70% of mutant alleles are of missense type; the remainder are null mutations 
(deletion/insertion causing frame shifting, nonsense, and splice site mutations), large genomic rearrangements, and 
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synonymous or intronic changes causing aberrant splicing. 
While the truncating mutations are considered to be causative, the pathological significance of nucleotide 
changes localized in intronic regions is very difficult to predict, which makes distinguishing between benign and 
pathogenetic variants a challenge and compromises a conclusive genetic counselling. Indeed, many intronic 
changes remain of uncertain clinical significance (UVs), thus partially explaining the observation that, although a 
severe calpain-3 protein defect in muscle usually corresponds to primary LGMD2A, about 20% of biochemical 
defects remain without any molecular proof [Fanin et al., 2009a]. Many CAPN3 intronic variants have been 
identified during diagnostic screening: they account for about 15% of the total variants listed at the Leiden 
Database (28% in splice sites, 72% in deep intronic position), and for about 25% of the mutations reported in other 
studies [Blazquez et al., 2008; Krahn et al., 2006]. However, it is conceivable that the true frequency of intronic 
mutations has largely been underestimated because deep intronic sequences are not conventionally sequenced and, 
most aberrant transcripts are expressed at low abundance and are usually prone to degradation by nonsense-
mediated mRNA decay (NMD) mechanism [Maquat, 2004]. For the majority of intronic variants the consequences 
on mRNA splicing have been only inferred by in-silico analysis [Duno et al., 2008], whereas experimental 
demonstration of their pathogenicity has been obtained by mRNA studies for only 1% of them [Leiden Database; 
Haffner et al., 1998; Krahn et al., 2007; Blazquez et al., 2008]. In this study we have exploited the availability of 
diagnostic muscle biopsies to demonstrate previously unrecognized pathogenetic effects, at both transcriptional 
and translational levels, of 5 different intronic mutations in the CAPN3 gene. 
MATERIALS AND METHODS 
Selection of patients and muscle biopsies 
From a population of over 100 LGMD2A patients who had received a biochemical and genetic characterization 
in our Centre, 16 cases were selected because of the presence of one intronic variant in the CAPN3 gene with an 
unknown pathogenetic effect. In all cases except one, the second mutant allele has been identified. Patients 
underwent diagnostic open muscle biopsies, after written consent had been obtained. As normal controls, we used 
genomic DNA, cDNA from muscle tissue and calpain-3 protein from subjects who had resulted free of any 
neuromuscular disorders. 
Protein analysis by western blotting 
Semi-quantitative analysis of calpain-3 protein in muscle was conducted as reported [Fanin et al. 2009b]. The 
quantity of immunoreactive bands at 94 kDa (full-length protein) was determined by densitometry and expressed 
as a percentage of control.  
In-silico analysis of unclassified intronic variants (UVs)  
Prediction of the potential effect of intronic variants was determined by the following splice-site prediction 
programs (SSPPs): Human Splicing Finder (HSF V2.4 at http://www.umd.be/HSF) [Desmet et al., 2009], Splice 
Site prediction by Neural Network (NNSPLICE V0.9 at www.fruitfly.org/seq_tools/splice.html), Splice View 
(http://bioinfo.itb.cnr.it/oriel/splice-view.html) and NetGene2 (at www.cbs.dtu.dk/services/NetGene2). Score 
variation in canonical splice-site use and potential activation of cryptic splice-sites in the presence of mutations 
were evaluated by analysis of exon and intron sequences localized in proximity to mutations using default settings 
(Supp. Table S1). 
RNA analysis  
Total RNA was isolated from muscle biopsies using the SV Total RNA Isolation System kit (Promega, 
Madison, WI) including treatment with DNAsel, and reverse transcribed to cDNA with Superscript III reverse 
transcriptase (Invitrogen, San Diego, CA) and random hexamers. In one patient the total RNA was isolated also 
from blood using the PAXGene blood RNA System (PreAnalytiX, Qiagen, Hilden, Germany). cDNA was 
amplified with specific calpain-3 primers designed on the published human calpain-3 mRNA sequence (GenBank 
accession number: NM_000070). PCR products were analyzed by gel electrophoresis: aberrant bands were 
manually excised and processed using the QIAquick Gel Extraction kit (Qiagen) for sequencing. Furthermore, we 
designed splicing-specific and skipping-specific primers (sequence available on request) to selectively amplify E1660  Nascimbeni et al. 
abnormal transcripts predicted by bioinformatic tools, even when this was not detectable on RT-PCR. Each 
splicing-specific PCR was tested on both patients and normal controls and directly sequenced. Details of in-silico 
predictions of splicing are reported in Supp. Table S1.  
RESULTS 
We investigated the pathogenetic effect in muscle of 5 different intronic variants (one novel) in the CAPN3 
gene, including 3 nucleotide substitutions in the canonical donor or acceptor splice sites and 2 more deep intronic 
variations, and demonstrated that they all caused abnormal mRNA splicing and abolished or impaired protein 
synthesis (Table 1, Table 2, Supp. Table S1). These intronic mutations accounted for 9% of the total mutant alleles 
and 7% of all the mutations found in our population of over 100 LGMD2A patients. 
Variation c.1030-1G>A (intron 7) 
This was the first time this mutation had been identified in an LGMD2A patient. The patient was a compound 
heterozygote for a null mutant allele (c.550delA). This mutation abolishes the canonical acceptor splice-site, but 
the expected skipping of exon 8 was not detected. From SSPPs analysis, this intronic variant was expected to 
create a novel acceptor splice site (A1) with consequent deletion of the first nucleotide of exon 8 (r.1030delG). 
cDNA sequencing confirmed this deletion, which resulted in the creation of a downstream premature stop codon 
(p.V344SfsX8). Calpain-3 protein in muscle was absent, demonstrating the deleterious effect of this mutation at 
translational level. 
Variation c.1524+1G>C (intron 11) 
This mutation was identified in one LGMD2A patient in our series, who was a compound heterozygote for a 
missense mutant allele (p.M252T) and showed severely reduced calpain-3 protein level in muscle (5% of control), 
revealing its deleterious effects at translational level. This mutation abolishes the canonical donor splice-site, but a 
transcript carrying the skipping of exon 11 was not detected, even when using skipping-specific primers. 
Following SSPPs analysis, this variant was expected to produce two different aberrant transcripts (Figure 1): one 
originated by the use of a cryptic donor site (D1), leading to a deletion of the last 99 basepairs in exon 11 
(r.1425_1524del), and another (D2) resulting from the exonization (intron retention) of 212 basepairs in intron 11 
(r.1524_1525ins1524+1_1524+31;1524+1g>c; p.E508_V509ins 508+1_508+70). D1 transcript was characterized 
by cDNA amplification, which showed a shortened product corresponding to the expected deletion, that was 
identified by sequencing (p.V476_E508del). A further confirmation was obtained by PCR with D1 splicing-
specific primers. While this transcript was sufficiently expressed and stable enough to be easily detected by cDNA 
analysis in muscle, the D2 transcript was detected only by splicing-specific PCR. 
Variation c.1992+1G>T (intron 17) 
This mutation was identified in 3 unrelated LGMD2A patients in our series; its deleterious effect at translational 
level was demonstrated by the observation that it was associated with absent or virtually absent protein when 
found in a compound heterozygote state with different mutant alleles. The mutation abolishes the canonical donor 
splice-site and we demonstrated that it caused the skipping of the exon 17 (r.1915_1992del; p.P639_D664del) in 
muscle. This result was confirmed also in blood mRNA from one patient. The resulting transcript (WTD) is 
probably unstable and poorly expressed, since it was detectable only with skipping-specific primers. At least 3 
cryptic splicing sites in the region surrounding this mutation obtained a high score from SSPPs analysis, but only 
one of them was shown to be effectively activated (D1) in muscle and blood cDNA by splicing-specific primers. 
This cryptic splice site generated an aberrant transcript carrying the insertion of 31 basepairs in intron 17 
(r.1992_1993ins1992+1_1992+31;1992+6g>u; p.D664_D665ins 664+1_664+10) (Figure 2). Pathogenetic Effect of Intronic CAPN3 Gene Mutations    E1661 
 
Table 1. Consequences of Intronic Mutations at RNA Level 
 
Intronic sequence 
variant * 
Alternative 
acceptor/donor 
site, position 
Effect at RNA level  Theoretical effect  at 
protein level *  Methods Interpretation 
c.1030-1G>A A1/  c.1030-1  r.1030delG 
deletion of the 
first bp exon 8 
p.V344SfsX8 cDNA  amplification,  sequencing pathogenetic 
c.1524+1G>C 
D1/c.1426  r.1425_1524del 
deletion of 
99 bp exon 11 
p.V476_E508del  cDNA amplification, gel extraction of 
aberrant band, sequencing  pathogenetic 
D2/c.1524+213  r.1524_1525ins1524+1_1
524+31;1524+1g>c 
exonization of 
212 bp intron 11 
p.E508_V509ins 
508+1_508+70  Splicing specific-PCR, sequencing  pathogenetic 
c.1992+1G>T 
WT D/c.1992+1  r.1915_1992del 
skipping of 
exon 17 
p.P639_D664del  Splicing specific-PCR, sequencing  pathogenetic 
D1/c.1992+32  r.1992_1993ins1992+1_1
992+31;1992+6g>u 
exonization of 
31 bp  intron 17 
p.D664_D665ins 
664+1_664+10  Splicing specific-PCR, sequencing  pathogenetic 
c.1193+6T>A D1/c.1193+32  r.1193_1194ins1193+1_1
193+31;1193+6u>a 
exonization of 
31 bp intron 9 
p.M399X  cDNA amplification, gel extraction of 
aberrant band, sequencing  pathogenetic 
c.1746-20C>G 
A1/ c.1746-21  r.1745_1746ins1746-
19_1746-1;1746-20c>g 
exonization of 
19 bp intron 13 
p.E582_E583ins 
582+1_582+6fsX9 
Splicing specific-PCR, gel extraction 
of aberrant band, sequencing  pathogenetic 
A2/ c.1746-88  r.1745_1746ins1746-
86_1746-1;1746-20c>g 
exonization of 
86 bp intron 13 
p.E582_E583ins582+
1_582+28fsX41 
Splicing specific-PCR, gel extraction 
of aberrant band, sequencing  pathogenetic 
A3/ c.1746-124  r.1745_1746ins1746-
122_1746-1;1746-20c>g 
exonization of 
122 bp intron 13 
p.E582_E583ins  
582+1_582+30fsX53 
Splicing specific-PCR, gel extraction 
of aberrant band, sequencing  pathogenetic 
A4/ c.1746-307  r.1745_1746ins1746-
305_1746-1;1746-20c>g 
exonization of 
305 bp intron 13 
p.E583X  Splicing specific-PCR, sequencing  pathogenetic 
WT A13/c.1537-2  r.1745_1746ins1745+1_1
746-1;1746-20c>g 
exonization of 
entire  intron 13 
p.E583X  Splicing specific-PCR, gel extraction 
of aberrant band, sequencing  non pathogenetic 
 
WT: Wild type; D: donor site; D1, D2, etc: alternative cryptic donor sites; A: acceptor site; A1, A2, etc: alternative cryptic acceptor sites; exonization: intron retention; *: Human 
Genetic Variation Society (HGVS) approved guidelines (www.hgvs.org/mutnomen). GenBank accession number AF209502.1.E1662  Nascimbeni et al. 
 
Figure 1. Splicing analysis of the c.1524+1 G>C variant. Panel A. Schematic representation of the splicing patterns generated 
by this variant: D1, carrying the deletion of the last 99bp of exon 11 (gray box), and D2, with the retention of 212bp of intron 
11 (dashed box), resulting from the use of the alternative donor splice sites D1 and D2, respectively. The arrows indicate the 
localization of the primers used. Panel B. Sequences from PCR amplification of muscle cDNA from a heterozygous mutant 
patient, showing the co-amplification of the wild-type (WT) and the alternately spliced mRNA (D1), and from splicing-specific 
PCR amplification, which selectively amplifies the allele carrying the mutation (D2) in the same patient. Panel C. RT-PCR 
analysis of normal control (C) and a heterozygous mutant patient (Pt.) who shows the WT product and two additional low-
abundant products corresponding to the alternately spliced mRNA (D1 and D2). Calpain-3 western blot shows that this 
mutation caused a severe reduction of protein (Pt.) corresponding to about 5% of control (C) after myosin normalization. 
 
Figure 2. Splicing analysis of the c.1992+1 G>T variant. Panel A. Schematic representation of the two splicing patterns 
generated by this variant: WTD, carrying the skipping of exon 17, and D1, with the retention of 31bp of intron 17 (dashed box), 
resulting from the use of the alternative donor splice site D1. The arrows indicate the localization of the primers used. Panel B. 
Sequences from splicing-specific PCR amplification of muscle cDNA from a heterozygous mutant patient, showing the two 
aberrant transcripts (WTD and D1) generated by this variant. Panel C. Splicing-specific PCR amplification showing the 
selective amplification of the aberrant transcripts generated by this variant (WTD and D1) only in the heterozygous mutant 
patient (Pt.). Calpain-3 western blot in a patient (Pt.) shows that this mutation produced absent protein. Pathogenetic Effect of Intronic CAPN3 Gene Mutations    E1663 
 
Variation c.1193+6T>A (intron 9) 
This mutation was identified in 6 unrelated LGMD2A patients in our series, all from the same administrative 
district of the Veneto Region (a possible founder effect followed by genetic isolation might have occurred). 
Among the 6 patients with this mutation, one was the object of a family study (Figure 3): we conducted both a 
segregation analysis of the mutant allele and a study of the effect of this mutation at calpain-3 protein level in 2 
different family members (a muscle biopsy was obtained from both an affected girl and her heterozygote father, 
who reported hyperCKemia before the diagnosis was obtained in his daughter).  
The deleterious effect of this mutation at translational level was demonstrated by the observation that: 1) when 
it was associated with a null mutant allele, it produced absent or very reduced amounts of protein. This variant was 
not predicted to cause the loss of the canonical donor splice site, but the score for its use was reduced by all the 
SSPPs algorithms used. This means that the generation of a correctly spliced transcript would still be possible in-
vivo, but our protein data suggest that, if this is the case, this might only take place to a very limited extent; 2) 
when it was expressed in heterozygote state, it produced one half of the amount of protein; 3) when associated 
with a missense mutant allele, which, as we had previously reported, caused the loss of functional autolytic activity 
without any quantitative defect, it produced normal protein quantities. Furthermore, following SSPPs analysis, this 
variation was expected to affect correct splicing by use of an alternative cryptic donor splice site (D1), resulting in 
the insertion of 31 basepairs at the beginning of intron 9 (r.1193_1194ins1193+1_1193+31; 1193+6u>a; 
p.M399X). The D1 transcript was sufficiently expressed to be detected by RT-PCR analysis: it produced an extra-
band which was detectable after gel electrophoresis and which was excised and sequenced (Figure 3). No previous 
functional characterization of this mutation has been provided. 
 
 
Figure 3. Splicing analysis and translational effect of the c. 1193+6 T>A variant. Panel A. Schematic representation of the 
aberrant splicing product (D1) generated by this variant, carrying the insertion of 31bp of intron 9 (dashed box) and resulting 
from the use of the alternative donor splice site D1. The arrows indicate the localization of the primers used. Panel B. Sequence 
from PCR amplification of muscle cDNA from a heterozygous mutant patient, showing the co-amplification of the WT and the 
alternately spliced mRNA (D1). Panel C. RT-PCR analysis of normal control (C) and a heterozygous mutant patient (II-1) who 
shows the WT product and one additional low-abundance product corresponding to the alternately spliced mRNA (D1). Family 
pedigree (case n. 7652) and western blot show that this intronic mutation (filled symbol) produced a reduction of calpain-3 
protein of about 50% of control (C) after myosin normalization, as assessed in the muscle biopsy from both the heterozygous 
father (I-1) and his affected daughter (II-1), who was a compound heterozygote for a second missense mutation (p.E435K, 
dashed symbol). 
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Variation c.1746-20C>G (intron 13) 
This mutation was identified in 6 unrelated LGMD2A patients in our series, and also in several previous 
reports, where its pathogenetic effects have been suggested [Piluso et al., 2005; Hermanova et al., 2006; Leiden 
Database], but unsupported by experimental data [Stehlikova et al., 2007; Krahn et al., 2007], or even reported as a 
polymorphism [Groen et al., 2007; Leiden Database].  
Conversely, in our study, the deleterious effect of this mutation has definitely been demonstrated at both 
translational (when this mutation was associated with another mutant allele, it always resulted in severely reduced 
protein quantity; Figure 4) and transcriptional levels. Indeed, this mutation had been predicted by the HSF 
algorithm to create a new acceptor splice site (A1), which was detected in muscle mRNA by splicing-specific 
PCR. Furthermore, numerous cryptic splicing sites in the region surrounding this mutation obtained a high score 
by SSPPs analysis and were expected to cause the insertion of different portions of intron 13. Three such 
transcripts (A2, A3, A4) were detected in our patients by cDNA analysis. However, even though none of the 
algorithms used predicted the loss of the canonical acceptor splice site (and only a slight decrease in its score was 
obtained for two of them), we identified an aberrant transcript (WTA) carrying the insertion of the entire intron 13. 
All these transcripts were variably expressed and detected in the patients, but while 4 aberrant transcripts (A1, A2, 
A3, A4) were detected only in mutant patients, suggesting their pathogenetic effect, the variant WTA was also 
expressed in 10 normal controls, indicating its non-pathogenicity. We attribute the occurrence of this latter 
transcript to the result of an alternative splicing event that takes place in normal tissues, as previously reported 
[Kawabata et al., 2003; De Tullio et al., 2003]. 
 
 
Figure 4. Splicing analysis and translational effect of the c. 1746-20 C>G variant. Panel A. Schematic representation of the 5 
splicing patterns generated by this variant, resulting from the use of the cryptic acceptor splice sites A1, A2, A3, A4, carrying 
the retention of 19, 86, 122 and 305 bp of intron 13 (dashed boxes), respectively, and WTA13, with the retention of the entire 
intron 13 (dashed box). The arrows indicate the localization of the primers used. Panel B. Splicing-specific PCR (designed to 
potentially amplify all the 5 aberrant transcripts) showing that these transcripts are variably expressed and not always detectable 
in the heterozygous mutant patients (Pt.1, II-1, and Pt.3). The WTA transcript is expressed also in normal control (C). Panel C. 
Family pedigree (case n. 6211) and western blot showing that this intronic mutation (filled symbol) produced a deleterious 
effect at protein level, as demonstrated by the complete loss of calpain-3 protein in the muscle from one affected patient (II-1) 
who was a compound heterozygote for a second missense mutation that has a deleterious effect as well (p.L204V, dashed 
symbol).Pathogenetic Effect of Intronic CAPN3 Gene Mutations    E1665 
 
 
Table 2. Consequences of Intronic Mutations at Protein Level 
 
Intronic sequence 
variant *  Case N.  Second mutant allele  Protein amount 
(% of control) 
c.1030-1G>A  7161 c.550delA,  p.T184RfsX36  0 
c.1524+1G>C  7555 c.755T>C,  p.M252T  5 
c.1992+1G>T 
1324 c.1193+6T>A  0 
1754 c.1061T>G,  p.V354G  0 
5393 c.1343G>A,  p.R448H  0 
c.1193+6T>A 
1324 c.1992+1G>T  0 
3393 c.1468C>T,  p.R490W  100§ 
5427 not  identified  20 
6804 c.309+4469_1116-1204del,  p.E104MfsX11  20 
7652 c.1303G>A,  p.E435K  50 
8242 c.  1469G>A,  p.R490Q  100§ 
c.1746-20C>G 
1338 c.1333G>A,  p.G445R  0 
2522 c.245C>T,  p.P82L  20 
4622 c.1061T>G,  p.V354G  10 
6211 c.610C>G,  p.L204V  0 
6385 c.550delA,  p.T184RfsX36  5 
7894 c.697G>C,  p.G233R  10 
*: Human Genetic Variation Society (HGVS) approved guidelines (www.hgvs.org/mutnomen). GenBank accession number 
AF209502.1. §: protein with loss of function (autolytic activity). 
DISCUSSION 
Despite the frequent identification of intronic changes in the CAPN3 gene, the demonstration of their 
pathogenetic effect has only occasionally been sought or achieved, both due to the laborious investigations 
involved and, also, because mRNA/protein studies in LGMD2A are often limited by the unavailability of a muscle 
biopsy. Although assessment of the pathogenetic effects of such variants is challenging, the effort required is 
justified because successful results are crucial to offer definitive diagnoses and conclusive genetic counseling, 
when establishing genotype-phenotype correlations and in view of future therapies. 
Using  in-silico predictions combined with RT-PCR analyses on muscle mRNA, we demonstrated the 
pathological significance of 5 UVs, showing their effects on splicing and protein translation.  
We showed that CAPN3 mRNA degradation by NMD is not a drawback in muscle RT-PCR analyses, provided 
that these are combined with SSPPs analysis and the use of splicing-specific PCR tests. SSPPs are valuable tools to 
select variants that are predicted to impair correct RNA splicing, for address the subsequent variant-specific 
analyses at RNA level. However, they may provide contradictory or negative results, requiring the use of multiple 
softwares to resolve the discrepancies. Among the 4 softwares we used in this study, the most reliable and 
informative was the HSF, which contains also matrices for the prediction of effects on putative enhancer/silencer 
sequences. 
Previous studies have reported different results for 3 of the 5 variants we analyzed (c.1992+1G>T, 
c.1524+1G>C and c.1746-20C>G). In particular, one study on blood mRNA identified only one aberrant transcript 
(D1) for the mutation c.1992+1G>T and failed to detect any mRNA for the mutation c.1524+1G>C [Blazquez et E1666  Nascimbeni et al. 
al., 2008]. We suggest that this discrepancy could be due to the different approach used. Indeed, using splicing-
specific PCR, combined with in-silico predictions, we demonstrated that all the aberrant transcripts for the 
c.1992+1G>T mutation identified in muscle were expressed also in blood. Another possible explanation may be 
the use of a tissue other than muscle. Earlier studies reported the unreliability of RNA splicing analysis from blood 
samples, both because of its different splicing pattern and of the possibility that degenerated or illegitimate splicing 
had occurred associated with diverse storage conditions [Wimmer et al., 2000]. These observations highlight how 
critical the choice of the tissue to be studied is. Furthermore, because of the lack of a molecular proof, some 
intronic variants have been reported either as polymorphisms or as “possibly pathogenetic”, thus generating 
confusion and compromising a conclusive genetic counselling. This is the case of the variation c.1746-20C>G in 
intron 13 [Hermanova et al., 2006; Stehlikova et al., 2007; Krahn et al., 2007; Groen et al., 2007], for which we 
have provided a definite demonstration of the pathogenetic effect.  
In our study, the 3 mutations localized at conserved canonical donor/acceptor splice sites showed clearly their 
pathogenicity at both RNA and protein level, causing the loss of splice site and resulting in the absence of protein. 
For the 2 mutations localized in less conserved regions nearby the exon/intron boundaries, SSPPs did not predict 
the loss of canonical splice sites, but only provided a decreased score, indicating a higher probability of use of 
nearby cryptic splicing sites, which indeed we experimentally demonstrated. Patients carrying these 2 latter 
mutations and heterozygous for a different frame-shifting mutation showed either absent or severely reduced 
calpain-3 protein, indicating that if a correct splicing were still possible, it might occur to a very limited extent.  
The majority of the aberrant transcripts characterized in this study both contained a frame-shifting and either 
were expressed at very low abundance or were detectable only by splicing-specific-PCR. This result agrees with 
trace amounts of the corresponding transcript identified in LGMD2A patients who were compound heterozygous 
for 2 null mutations [Stehlikova et al., 2007]. Conversely, the transcripts originating from the c.1524+1G>C and 
c.1992+1G>T variants contained in-frame insertions/deletions, which were however expressed at low abundance, 
possibly because alternative splicing may limit the export of mRNA, making it a target for degradation. These 
transcripts could potentially have generated longer/truncated protein products, which were however not detected. 
One conclusion from our study is that although SSPPs analysis helps in addressing the potential effects of 
intronic variations, experimental demonstration of this is not always easy to do by mRNA analysis (low abundance 
of transcripts, NMD mechanism) and might prove unsuccessful unless the individual transcripts are identified by 
both splicing-specific-PCR tests and sequencing. Furthermore, SSPPs analysis proved to be very valuable and 
reliable in predicting aberrant splicing for variants localized in the intronic 5’ and 3’ splice-site region, whereas it 
was neither conclusive nor always successful in the prediction of the consequences of such loss. For this purpose, 
however, it was useful to check the regions surrounding the nucleotide variant for the presence of potential cryptic 
splicing sites and for the loss/gain of splicing regulatory elements [Faustino and Cooper, 2003; Shapiro and 
Senapathy, 1987]. 
We verified that a common effect of intronic variations in the CAPN3 gene, occurring in all 5 mutations 
studied, is the aberrant splicing caused by the activation of a series of cryptic splicing sites near the mutant 
nucleotide, and the creation/disruption of potential silencer/enhancer motifs. Mutation analysis by SSPPs should 
therefore involve the sequence context, in order to obtain more informative predictions. Conversely, the 
occurrence of exon skipping was observed only in one case in our series, suggesting either that this a less frequent 
mechanism used for the variants analysed (possibly because of the presence of a nearby cryptic splice site) or that 
transcripts carrying exon-skipping are more unstable and prone to degradation by NMD.  
Although experimental demonstration of the pathogenetic effects of intronic mutations is difficult and 
laborious, we found that it is often successful when this effort is based on a preliminary SSPPs analysis. This aim 
should be pursued more frequently because of its important consequences for clinical and genetic counselling, for 
establishing genotype-phenotype correlations and providing novel insights into the complex mechanism of 
splicing. 
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Supp. Table S1. Software Predicted Effect of Intronic Variations at cDNA Level 
 
Intronic 
sequence 
variant 
Transcripts 
HSF (range 0-100) NetGene2  (range 0-1) SpliceView  (range 0-100) NNSplice  (range 0-1) 
CV for 
WT seq. 
CV for 
mutant 
seq. 
CV Var. %  
CV for 
WT seq. 
CV for 
mutant 
seq. 
CV 
Var. 
% 
CV for 
WT 
seq. 
CV for 
mutant 
seq. 
CV Var. 
% 
CV 
for 
WT 
seq. 
CV for 
mutant 
seq. 
CV 
Var. 
% 
c.1030-1G>A 
WT A  79.96 51.02  -36.2  SB 0.19  0  SB  82 - SB  0.69 -  SB 
A1/ c.1030-1  46.54 75.48 +62.2  NS  0 0.14  NS  0 79 NS  - - - 
c.1524+1G>C 
WT D  86.1 59.27  -31.17  SB 0.93  0  SB  84 - SB  0.91 -  SB 
D1/ c.1426  84.76 84.76  0  -  -  -  83  83  0  -  -  - 
D2/ c.1524+213  86.43 86.43  0  -  -  -  78  78  0  -  -  - 
c.1992+1G>T 
WT D  86.21 59.38 -31.13  SB 0.95  -  SB  86 - SB  0.97 -  SB 
D1/ c.1992+32  77.72 77.72  0  -  -  -  81 81  0 0.78  0.78 0 
* D2/ c.1943  85.38 85.38  0  -  -  -  84 84  0  -  -  - 
* D3/ c.1992+96  81.2 81.2  0  -  -  -  - -  -  - - - 
c.1193+6T>A 
WT D  94.09 91.76  -2.48  1  0.95  -5  89  86  -3.4 0.98 0.95 -3.1 
D1/ c.1193+32  92.26 92.26  0  0.89  0.93 +4.5  89 89  0  0.99 0.99  0 
c.1746-20C>G 
WT A  93.39 93.39  0  -  -  -  88  87  -1.14 0.95 0.93  -2.11 
A1/ c.1746-21  54.37 83.31 +53.24  NS  -  -  - - -  - - - - 
A2/ c.1746-88  88.06 88.06  0  0.18  0.19 +5.55 81  81  0  0.67 0.67  0 
A3/ c.1746-124  82.52 82.52  0  -  -  -  77  77  0  -  -  - 
A4/ c.1746-307  84.93 84.93  0  0.43  0.43  0  85  85  0  0.60 0.60  0 
* A5/ c.1746-550  86.86 86.86  0  -  -  -  80  80  0  0.65 0.65  0 
* A6/ c.1746-644  94.5 94.5  0  -  -  -  86 86  0 0.74  0.74 0 
WT A: Wild type acceptor site; WT D: Wild type donor site; D1, D2, etc: alternative cryptic donor sites; A1, A2, etc: alternative cryptic acceptor sites; CV: consensus value; 
Var.%: CV variation between WT and mutated sequence; SB: site broken. NS: new site; *: transcripts not detected by cDNA analysis;  - : site not detected by the software. 
 